The Human Immunology Project Consortium (HIPC) program was established in 2010 by the NIAID Division of Allergy, Immunology, and Transplantation as part of the overall NIAID focus on human immunology. Since its inception, 13 HIPC centers have been awarded, with 9 of these sites currently active. The goal of HIPC is to provide a comprehensive understanding of the human immune system and its regulation by revealing novel associations between components of the immune system and other biological systems, identifying novel immune mediators and pathways, establishing predictors of vaccine safety in different populations, and enabling the rapid evaluation of different vaccine formulations and administration regimens in human populations. Well-characterized human cohorts are studied (in the context of infection, vaccination, and immune-mediated diseases) using a variety of modern analytic tools, including multiplex transcriptional, cytokine, metabolomic, and proteomic assays; multiparameter phenotyping of immune cell subsets; assessment of immune cell functional status; and multiple computational methods.

Through the HIPC program, centralized research resources including access to all of the data generated through the program, the development of Data Standards for human immunology studies, and ImmuneSpace for integrative modeling of human immunology data are available for use by the greater scientific community.